Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.77 |
| ▸ | PTGDR2 | Q9Y5Y4 | 15/20 | 0.68 |
| ▸ | PTGDR | Q13258 | 5/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4628496 | 0.88 | MAPT (0.79) | MAPTPTGDR2PTGDRTDP1TSHR | |
| SCHEMBL5262170 | 0.87 | MAPT (0.72) | MAPTPTGDR2PTGDRTDP1TSHR | |
| SCHEMBL14340636 | 0.87 | MAPT (0.77) | MAPTPTGDR2PTGDRTDP1TSHR | |
| SCHEMBL121636 | 0.87 | MAPT (1.00) | MAPTPTGDR2PTGDRTDP1TSHR | |
| SCHEMBL11110347 | 0.85 | MAPT (0.74) | MAPTPTGDR2PTGDRTDP1TSHR | |
| SCHEMBL11106300 | 0.85 | MAPT (0.74) | MAPTPTGDR2PTGDRTDP1TSHR | |
| SCHEMBL12463783 | 0.85 | MAPT (0.74) | MAPTPTGDR2PTGDRTDP1TSHR | |
| SCHEMBL12830790 | 0.85 | MAPT (0.74) | MAPTPTGDR2PTGDRTDP1TSHR | |
| SCHEMBL1372961 | 0.85 | MAPT (0.97) | MAPTPTGDR2PTGDRTDP1TSHR | |
| SCHEMBL2591610 | 0.85 | MAPT (0.97) | MAPTPTGDR2PTGDRTDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1763509-B1 | ALPHA-HELICAL MIMETICS | WALTER & ELIZA HALL INST MEDICAL RES (AU) | 2018-02-21 | — | — | EP | disclosed |
| US-7956216-B2 | Benzoyl urea derivatives mimicing BH3-only proteins, able to interact with a Bcl-2 protein | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2011-06-07 | — | — | US | disclosed |
| US-7956216-B2 | Benzoyl urea derivatives mimicing BH3-only proteins, able to interact with a Bcl-2 protein | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2011-06-07 | — | — | US | disclosed |
| US-20080153802-A1 | Alpha-helical mimetics | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2008-06-26 | — | — | US | disclosed |
| US-20080153802-A1 | Alpha-helical mimetics | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2008-06-26 | — | — | US | disclosed |
| US-4461905-A | THROMBOXANE SYNTHETASE INHIBITOR INTERMEDIATE | ONO PHARMACEUTICAL CO., LTD. (JP) | 1984-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153802-A1 | Alpha-helical mimetics | BID, BAX, BAD | MAPT 781/4885PTGDR2 3802/4885PTGDR 3979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.